These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 36079070)

  • 1. Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus-From Prevalence to Diagnostic Approach and Treatment Strategies.
    Diaconu CT; Guja C
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
    Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
    Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.
    Targher G; Corey KE; Byrne CD; Roden M
    Nat Rev Gastroenterol Hepatol; 2021 Sep; 18(9):599-612. PubMed ID: 33972770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Kosmalski M; Ziółkowska S; Czarny P; Szemraj J; Pietras T
    J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Dharmalingam M; Yamasandhi PG
    Indian J Endocrinol Metab; 2018; 22(3):421-428. PubMed ID: 30090738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.
    Bril F; Cusi K
    Endocrinol Metab Clin North Am; 2016 Dec; 45(4):765-781. PubMed ID: 27823604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic steatohepatitis: global impact and clinical consequences.
    Kabarra K; Golabi P; Younossi ZM
    Endocr Connect; 2021 Oct; 10(10):R240-R247. PubMed ID: 34486981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nonalcoholic fatty liver disease : Hepatic manifestations of metabolic syndrome].
    Roeb E
    Inn Med (Heidelb); 2023 Apr; 64(4):323-328. PubMed ID: 36580094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship.
    Muzica CM; Sfarti C; Trifan A; Zenovia S; Cuciureanu T; Nastasa R; Huiban L; Cojocariu C; Singeap AM; Girleanu I; Chiriac S; Stanciu C
    Can J Gastroenterol Hepatol; 2020; 2020():6638306. PubMed ID: 33425804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus.
    Bhardwaj M; Mazumder PM
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; ():. PubMed ID: 38861011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease.
    Iqbal U; Perumpail BJ; Akhtar D; Kim D; Ahmed A
    Medicines (Basel); 2019 Mar; 6(1):. PubMed ID: 30889791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease.
    Manka PP; Kaya E; Canbay A; Syn WK
    Dig Dis Sci; 2021 Nov; 66(11):3676-3688. PubMed ID: 34410573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.
    Caussy C; Aubin A; Loomba R
    Curr Diab Rep; 2021 Mar; 21(5):15. PubMed ID: 33742318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).
    Lomonaco R; Chen J; Cusi K
    Ther Adv Endocrinol Metab; 2011 Oct; 2(5):211-25. PubMed ID: 23148186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.